2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
09/13/17ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
YONKERS, N.Y., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will present a corporate overview at the 2017 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 3:25 PM ET in New York,... 
 Printer Friendly Version
09/11/17ContraFect to Present at 2017 World Antimicrobial Resistance Congress
YONKERS, N.Y., Sept. 11, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Executive Vice President of Research and Development and Chief Medical Officer at ContraFect, will be presenting at the 2017 World Antimicrobial Resistance Congress, to be held on September 14-15 in Washington... 
 Printer Friendly Version
08/09/17ContraFect Announces Second Quarter 2017 Financial Results
YONKERS, NY -- (Marketwired) -- 08/09/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the second quarter ended June 30, 2017. During the second quarter of 2017, ContraFect initiated conduct of a multicenter, multinational Phase 2 clinical study of its novel lysin product ca... 
 Printer Friendly Version
08/03/17ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies
YONKERS, NY -- (Marketwired) -- 08/03/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,718,875, which is assigned to ContraFect and expires on March 14, 2034. This patent includes claims related to the Company's... 
 Printer Friendly Version
07/20/17ContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants
YONKERS, NY -- (Marketwired) -- 07/20/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares of common stock with an exercise price of $1.55 per share at a combined public offering price of $1.2... 
 Printer Friendly Version
07/19/17ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
YONKERS, NY -- (Marketwired) -- 07/19/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase additional shares of its common stock. All of the securities in the offering are to be sold by ContraFect. Piper Jaffray & Co. is acting... 
 Printer Friendly Version
06/01/17ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017
YONKERS, NY -- (Marketwired) -- 06/01/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces five poster presentations of new data from the CF-301 development program at the American Society for Microbiology (ASM) Microbe 2017 conference to be held on June 1-5, 2017 in New Orleans, LA. Contra... 
 Printer Friendly Version
05/30/17ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave
YONKERS, NY -- (Marketwired) -- 05/30/17 -- ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Chairman of ContraFect's Board of Directors, intends to return from his temporary medical leave to resume his role as Chief Executive Officer on June 1, 2017. "I want to th... 
 Printer Friendly Version
05/25/17ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
YONKERS, NY -- (Marketwired) -- 05/25/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential treatment of Staphylococcus aureus (Staph aureus) bacteremia including right sided endocardi... 
 Printer Friendly Version
05/08/17ContraFect Announces First Quarter 2017 Financial Results
YONKERS, NY -- (Marketwired) -- 05/08/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the first quarter ended March 31, 2017. The Company ended the first quarter with cash, cash equivalents, and marketable securities of $28.9 million. "During the quarter we made substantial... 
 Printer Friendly Version
04/19/17ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
YONKERS, NY -- (Marketwired) -- 04/19/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces the presentation of new data from its Phase 1 CF-301 study at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) to be held on April 22-25, 2017 in Vienna, Austria. Co... 
 Printer Friendly Version
03/30/17ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
YONKERS, NY -- (Marketwired) -- 03/30/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has been selected to receive a funding award from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This award will help accelerate ContraFect's development of... 
 Printer Friendly Version
03/15/17CORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
YONKERS, NY -- (Marketwired) -- 03/15/17 -- In the news release, "ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update," issued earlier today by ContraFect Corporation(NASDAQ: CFRX), we are advised by the company the financial tables included in the original release were incorrect. The correct financial tables appear below. The text beneath the tables has also been updated. Complete corrected text follows. ContraFect Reports Fourth Qua... 
 Printer Friendly Version
03/15/17ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
YONKERS, NY -- (Marketwired) -- 03/15/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the fourth quarter and full year ended December 31, 2016. The Company ended the fourth quarter with cash, cash equivalents, and marketable securities of $35.2 million. "Our team is focused on progressing the de... 
 Printer Friendly Version
03/13/17ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
YONKERS, NY -- (Marketwired) -- 03/13/17 -- ContraFect Corporation (NASDAQ: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chief Executive Officer and Chairman of the Board, will be on medical leave from his CEO position as of March 16, 2017. Dr. Gilman w... 
 Printer Friendly Version
02/15/17Lisa Ricciardi to Join Board of Directors
YONKERS, NY -- (Marketwired) -- 02/15/17 -- ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that it has appointed Lisa Ricciardi to its Board of Directors. Ms. Ricciardi is a Life Sciences executive with deep business development and operational experience. She has worked for top pharmaceutical, payer, and molecul... 
 Printer Friendly Version
01/06/17ContraFect Provides Program Update
YONKERS, NY -- (Marketwired) -- 01/06/17 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today provided an update on its clinical development timeline for CF-301. The company now expects to initiate the Phase 2 study of CF-301 in patients with Staphylococcus aureus (Staph aureus) ... 
 Printer Friendly Version
01/04/17ContraFect to Present at Biotech Showcase 2017 Conference
YONKERS, NY -- (Marketwired) -- 01/04/17 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that Steven C. Gilman, PhD, the Company's Chairman and Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2017 conference on Tuesday, January 10, 2017 at 9:... 
 Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share

X
| E-mail Alerts E-mail Alerts | IR Contacts Contact IR | Financial Tear Sheet Tear Sheet